Agilent Technologies, Inc. (A)

Agilent Technologies, Inc. (A) Healthcare & Pipeline Overview

Agilent Technologies, Inc. delivers application-focused solutions for the life sciences, diagnostics, and applied chemical markets, featuring chromatography, mass spectrometry, and genomics technologies. With a strong emphasis on innovation and a global presence, Agilent supports research and development across various industries, maintaining a competitive edge through its comprehensive product offerings and service solutions.

What Is the Investment Thesis for A?

Agilent Technologies, Inc. presents a notable research candidate due to its strong market position, diverse product portfolio, and consistent financial performance. With a market capitalization of $36.91B and a P/E ratio of 27.1, Agilent demonstrates financial stability and growth potential. The company's profit margin of 18.3% and gross margin of 52.2% highlight its operational efficiency and pricing power. Key growth catalysts include increasing demand for advanced diagnostics and genomics solutions, as well as expansion in the life sciences and applied markets. Agilent's commitment to innovation and strategic acquisitions further strengthens its competitive advantage. However, potential risks include intense competition, regulatory challenges, and economic fluctuations. The company's beta of 1.31 indicates higher volatility compared to the market.

Based on FMP financials and quantitative analysis

A Key Highlights

• Market Cap of $36.91B reflects Agilent's significant presence and valuation in the diagnostics and research market.
• P/E Ratio of 27.1 indicates investor confidence in Agilent's earnings potential relative to its stock price.
• Profit Margin of 18.3% demonstrates Agilent's ability to generate profit from its revenue, showcasing operational efficiency.
• Gross Margin of 52.2% highlights Agilent's pricing power and efficient cost management in its product offerings.
• Dividend Yield of 0.65% provides a modest income stream for investors, indicating a stable financial position and commitment to shareholder returns.

Who Are A's Competitors?

A is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are A's Key Strengths?

• Diverse product portfolio serving multiple markets.
• Strong brand reputation and customer relationships.
• Global presence and extensive distribution network.
• Consistent financial performance and profitability.

What Are A's Weaknesses?

• Exposure to economic fluctuations and market volatility.
• Dependence on research and development for innovation.
• Intense competition in certain market segments.
• Potential for product recalls or quality issues.

What Could Drive A Stock Higher?

• New product launches in the diagnostics and genomics segments are expected to drive revenue growth in the next fiscal year.
• Increasing demand for personalized medicine and advanced diagnostics is fueling growth in Agilent's key markets.
• Strategic partnerships and collaborations with leading research institutions are enhancing Agilent's innovation pipeline.
• Expansion of Agilent CrossLab services is providing a recurring revenue stream and strengthening customer relationships.

What Are the Key Risks for A?

• Economic downturns could reduce demand for Agilent's products and services.
• Regulatory changes and compliance requirements could increase operating costs.
• Intense competition in the diagnostics and life sciences markets could impact market share and profitability.
• Supply chain disruptions could affect the availability of critical components and materials.
• Rapid technological advancements could lead to product obsolescence and the need for continuous innovation.

What Are the Growth Opportunities for A?

• Expansion in Genomics and Next-Generation Sequencing: Agilent can capitalize on the growing demand for genomics solutions, driven by advancements in next-generation sequencing (NGS) technologies. The global NGS market is projected to reach $25 billion by 2028. By investing in R&D and strategic partnerships, Agilent can enhance its NGS platforms and expand its market share in personalized medicine and diagnostics. This includes developing more efficient and cost-effective sequencing workflows.
• Growth in the Diagnostics Market: The diagnostics market is experiencing substantial growth, driven by the increasing prevalence of chronic diseases and the need for early and accurate diagnosis. Agilent can leverage its expertise in diagnostics to develop innovative solutions for disease detection and monitoring. The global diagnostics market is expected to reach $100 billion by 2028. Focusing on point-of-care diagnostics and molecular diagnostics can provide significant growth opportunities.
• Penetration of the Applied Chemical Market: Agilent has a strong presence in the applied chemical market, providing analytical solutions for various industries, including environmental testing, food safety, and petrochemicals. The company can further penetrate this market by developing application-specific solutions and expanding its service offerings. The applied chemical market is estimated to be worth $75 billion annually, offering ample opportunities for growth.
• Strategic Acquisitions and Partnerships: Agilent can pursue strategic acquisitions and partnerships to expand its product portfolio, enhance its technological capabilities, and enter new markets. By acquiring companies with complementary technologies and market access, Agilent can accelerate its growth and strengthen its competitive position. This includes partnerships with academic institutions and research organizations to drive innovation.
• Expansion of the Agilent CrossLab Services: The Agilent CrossLab segment offers a range of services, including startup, operational, training, compliance support, and asset management. Expanding these services can provide a recurring revenue stream and enhance customer loyalty. The global laboratory services market is projected to reach $40 billion by 2028. By offering comprehensive service solutions, Agilent can differentiate itself from competitors and capture a larger share of the market.

What Opportunities Does A Have?

• Expanding into emerging markets with high growth potential.
• Developing new diagnostic and therapeutic solutions.
• Leveraging data analytics and artificial intelligence.
• Acquiring complementary businesses and technologies.

What Threats Does A Face?

• Regulatory changes and compliance requirements.
• Technological obsolescence and disruption.
• Pricing pressures from competitors.
• Supply chain disruptions and geopolitical risks.

What Are A's Competitive Advantages?

• Strong brand reputation and customer loyalty.
• Extensive product portfolio and application-focused solutions.
• Global sales and service network.
• Significant investment in research and development.
• Proprietary technologies and intellectual property.

What Does A Do?

Agilent Technologies, Inc., established in 1999 and headquartered in Santa Clara, California, is a prominent provider of application-focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. Originating as a spin-off from Hewlett-Packard, Agilent has evolved into a leading player in its sectors, driven by innovation and strategic acquisitions. The company operates through three primary segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers a wide array of products, including liquid chromatography systems, mass spectrometry systems, gas chromatography systems, and various spectroscopy instruments. These tools are essential for research, development, and quality control across numerous industries. The Diagnostics and Genomics segment focuses on providing solutions for DNA mutation detection, genotyping, gene expression profiling, and next-generation sequencing. This segment also offers immunohistochemistry and hematoxylin and eosin staining. The Agilent CrossLab segment delivers GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies. Additionally, it provides a suite of services, including startup, operational, training, compliance support, and asset management. Agilent markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce, ensuring broad market coverage and accessibility. With a strong focus on customer needs and technological advancement, Agilent continues to drive innovation and growth in the life sciences and diagnostics industries.

What Products and Services Does A Offer?

• Develops and manufactures liquid chromatography systems and components.
• Offers liquid chromatography mass spectrometry systems for advanced analysis.
• Provides gas chromatography systems and components for various applications.
• Produces inductively coupled plasma mass spectrometry instruments.
• Offers arrays for DNA mutation detection and genotyping.
• Develops next-generation sequencing solutions and target enrichment technologies.
• Provides laboratory software and information management systems.
• Offers a range of services, including training, compliance support, and asset management.

How Does A Make Money?

• Sells analytical instruments and related consumables to life sciences, diagnostics, and applied chemical markets.
• Generates revenue through direct sales, distributors, resellers, and electronic commerce.
• Provides a range of services, including instrument maintenance, training, and consulting.
• Offers software solutions and data analytics tools for laboratory management and research.

What Industry Does A Operate In?

Agilent Technologies, Inc. operates in the rapidly evolving medical diagnostics and research industry, characterized by technological advancements and increasing demand for personalized medicine. The global diagnostics market is projected to reach $100 billion by 2028, driven by factors such as aging populations, rising healthcare expenditures, and advancements in genomics and proteomics. Agilent competes with major players like Becton, Dickinson and Company (BDX) and Edwards Lifesciences Corporation (EW), focusing on innovation and strategic partnerships to maintain its competitive edge. The industry is also subject to stringent regulatory requirements and evolving reimbursement policies, which impact market access and profitability.

Who Are A's Key Customers?

• Pharmaceutical and biotechnology companies.
• Academic and research institutions.
• Clinical diagnostic laboratories.
• Environmental testing facilities.
• Food and beverage companies.

Net buyingInsider Activity

Over the past six months, Agilent Technologies, Inc. insiders filed 23 SEC Form 4 transactions — 10 sales and 13 purchases. On net that is roughly 28K shares acquired (about $2.1M) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Agilent Technologies, Inc.

Revenue for Agilent Technologies, Inc. came in at $1.83B during Q2 2026, a 2.1% improvement versus the preceding quarter. The company recorded net income of $339.0M, with diluted EPS of $1.20. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, A averaged $1.24 in diluted EPS.

A Valuation & Market Position

With a $36.91B market cap, Agilent Technologies, Inc. sits in the large-cap segment of the market. Relative to its peer group, A's quantitative score of 83/100 is above the peer average of 71/100.

ROE 21%Key Financial Metrics

Return on equity for Agilent Technologies, Inc. stands at 20.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.8%, showing how much profit it generates from its asset base. A trades at a trailing price-to-earnings ratio of 27.13, above the Healthcare sector average of ~23x. Its free cash flow yield is 3.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.10 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.7%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 9/9Financial Health

Agilent Technologies, Inc.'s Piotroski F-Score is 9/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 5.12 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Agilent Technologies, Inc. revenue of about $7.44B for fiscal 2026, with EPS near $6.06. The estimate reflects 13 contributing analysts.

Company Profile

Agilent Technologies, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Santa Clara, US. The company is led by CEO Padraig McDonnell. A has traded publicly since 1999.

A Financials

A Latest News

A Analyst Consensus

A MoonshotScore

Agilent Technologies, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources